Constant Therapeutics today announced that its peptide drug TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7), will be tested in a Phase 2 clinical trial at Columbia University Irving Medical Center in New York, New York.… Read more »
Constant Therapeutics
Results: 13
Constant Therapeutics’ TXA127 to be tested in Multiple Clinical Trials for COVID-19 Patients
Constant Therapeutics today announced that its peptide drug TXA127 will be tested in a series of Phase 2 clinical trials in hospitalized COVID-19 patients who are not in the Intensive Care Unit (ICU)…… Read more »
Constant Pharmaceuticals, LLC Announces name change to Constant Therapeutics, LLC
Constant Pharmaceuticals, LLC, a privately held biopharmaceutical company focused on the treatment of stroke recovery and epidermolysis bullosa, today announced that they are changing their name to Constant Therapeutics, LLC.… Read more »
Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)
Constant Pharmaceuticals today announced that it plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, epidermolysis bullosa in collaboration with four EB focused charities – DEBRA (Austria), Cure-EB, the Epidermolysis Bullosa Research Partnership (EBRP), and the Epidermolysis Bullosa Medical Research Foundation (EBMRF).… Read more »
Constant Pharmaceuticals, LLC Announces European Patent Issuance for TXA127 in Treatment of Stroke
Constant Pharmaceuticals today announced that the European Patent Office (EPO) has notified the company that it will grant a patent covering the use of TXA127 in the treatment of stroke. … Read more »
Constant Pharmaceuticals, LLC Announces Japanese Patent Issuance for TXA302 in Treatment of Stroke
Constant Pharmaceuticals today announced that the Japanese Patent Office has issued a patent covering the use of TXA302 in the treatment of stroke. … Read more »
Tarix Orphan Receives Rare Pediatric Disease Designation for TXA127 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Cambridge, MA (January 18, 2017): Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease (RPD) designation for the company’s drug candidate TXA127 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. There are currently no approved therapies for RDEB and treatment […]
Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy (MDC1A)
Cambridge, MA (February 17, 2016): Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company’s lead compound, TXA127, for the treatment of laminin-‐deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). Early-‐onset LAMA2-‐related muscular dystrophy occurs in approximately 1 in 30,000 individuals and accounts for between […]
Tarix Orphan Receives FDA Fast Track Designation for TXA127 as Potential Treatment for Duchenne Muscular Dystrophy
Company Has “Green Light” to Proceed with Phase 2 Study, Planned to Initiate in Early 2016 Cambridge, MA (October 6, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation […]
Tarix Orphan, LLC Announces Patent Issuance for TXA127 in Treatment of Marfan Syndrome
TXA127 Shows Positive Activity in Fibrilin Model of Marfan Syndrome Cambridge, MA (August 18, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the use of TXA127 in […]
